MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...
Reprieve Cardiovascular today announced results for its first-in-human study of the Reprieve system for the treatment of acute decompensated heart failure (ADHF). The study focused on the device’s ...
BOSTON, MA—The Reprieve decongestion management system (Reprieve Cardiovascular) appears to safely manage patients hospitalized with acute heart failure (HF) and significant volume overload, according ...
(Nanowerk Spotlight) Cardiovascular diseases remain a leading cause of death worldwide, with atherosclerosis being a primary contributor. The narrowing of blood vessels due to plaque buildup can lead ...
During the conference, Mr. Pacyna will discuss Reprieve’s recent corporate and clinical milestones, including the ongoing enrollment in the Company’s pivotal FASTR II clinical trial. The presentation ...
-- Series B fundraise led by Deerfield Management enables scaling of pivotal clinical trial and commercial readiness activities for Reprieve® System – First patient enrolled in FASTR II study by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback